UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39049 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 20-0434866 (State or Other Jurisdiction of Incorporation or Organization) 1261 Lib ...

Exagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance for Full Year May 13, 2024 Carlsbad, Calif., – Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2024. First Quarter Highlights: "I'm thrilled with the strong start to the year, where we saw continued improvements in our key metrics, bringing us closer to our goal of profitability. Our volume increased in every month of the first quarter, and we ...

Exagen Inc. (NASDAQ:XGN) Q4 2023 Earnings Conference Call March 18, 2024 8:30 AM ET Company Participants John Aballi - President and CEO Kamal Adawi - CFO Ryan Douglas - IR Conference Call Participants Mark Massaro - BTIG Kyle Mikson - Canaccord Genuity Dan Brennan - TD Cowen Ross Osborn - Cantor Fitzgerald Andrew Brackmann - William Blair Operator Greetings. Welcome to Exagen Inc.’s Fourth Quarter 2023 Earnings Conference Call. [Operator Instructions] At this time, I’ll hand the conference over to Ryan Dou ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39049 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 20-0434866 (State or other jurisdiction of incorpor ...

Exagen Inc. (NASDAQ:XGN) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Ryan Douglas - IR John Aballi - President and CEO Kamal Adawi - CFO Conference Call Participants Kyle Mikson - Canaccord Genuity Mark Massaro - BTIG Dan Brennan - TD Cowen Andrew Brackmann - William Blair Operator Greetings, and welcome to the Exagen Inc. Third Quarter 2023 Earnings Conference Call. [Operator Instructions] And as a reminder, this conference is being recorded. And it is now my pleasure ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39049 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 20-0434866 (State or Other Jurisdiction of Incorporation or Organization) 1261 ...

Exagen Inc. (NASDAQ:XGN) Q2 2023 Earnings Conference Call August 7, 2023 8:30 AM ET Company Participants John Aballi - President and CEO Kamal Adawi - CFO Ryan Douglas - IR Conference Call Participants Dan Brennan - TD Cowen Mark Massaro - BTIG Dustin Scaringe - William Blair Kyle Mikson - Canaccord Ross Osborn - Cantor Fitzgerald Operator Greetings. Welcome to the Exagen Inc. Second Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will foll ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39049 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 20-0434866 (State or Other Jurisdiction of Incorporation or Organization) 1261 Libe ...

Exagen Inc. (NASDAQ:XGN) Q1 2023 Earnings Conference Call May 15, 2023 4:30 AM ET Company Participants Ryan Douglas - Investor Relations John Aballi - President & Chief Executive Officer Kamal Adawi - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Dan Brennan - TD Cowen Paul Knight - KeyBanc Operator Good day, ladies and gentlemen, and welcome to the Exagen Q1 2023 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39049 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 20-0434866 (State or other jurisdiction of incorporation or organization) 1261 Liberty Way Vista, California 92081 (Address of Principal Executive Offices) (Zip Code) (I.R. ...